Brimonidine
Loading...Brimonidine Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Brimonidine Tartrate Ophthalmic Solution is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The IOP lowering efficacy of Brimonidine Tartrate Ophthalmic Solution diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.
History
There is currently no drug history available for this drug.
Other Information
Brimonidine Tartrate Ophthalmic Solution, 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. The chemical name of brimonidine tartrate is 5-bromo-6 (2-imidazolidinylideneamino) quinoxaline L-tartrate. It is a white to slightly yellowish powder. In solution, brimonidine tartrate has a clear, greenish-yellow color. It has a molecular weight of 442.24 as the tartrate salt and is water soluble (34 mg/mL). The molecular formula is C11H10BrN5•C4O6; the structural formula is:
Brimonidine Tartrate Ophthalmic Solution, 0.2% is a sterile ophthalmic solution.
Each mL of Brimonidine Tartrate Solution contains:
ACTIVE: Brimonidine Tartrate 2 mg (equivalent to 1.32 mg as brimonidine free base).
PRESERVATIVE: Benzalkonium Chloride (0.05 mg)
INACTIVES: Citric Acid, Polyvinyl Alcohol, Sodium Chloride, Sodium Citrate; Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (5.6 to 6.6), and Water for Injection.
Sources
Brimonidine Manufacturers
-
Akorn, Inc.
![Brimonidine (Brimonidine Tartrate) Solution/ Drops [Akorn, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Brimonidine | Akorn, Inc.
The recommended dose is one drop of Brimonidine Tartrate Ophthalmic Solution in the affected eye(s) three times daily, approximately 8 hours apart.
Brimonidine Tartrate Ophthalmic Solution may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.
Login To Your Free Account